Teng Michele W L, Ngiow Shin Foong, Ribas Antoni, Smyth Mark J
Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. School of Medicine, University of Queensland, Herston, Queensland, Australia.
Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Cancer Res. 2015 Jun 1;75(11):2139-45. doi: 10.1158/0008-5472.CAN-15-0255.
Cancer immunotherapy may become a major treatment backbone in many cancers over the next decade. There are numerous immune cell types found in cancers and many components of an immune reaction to cancer. Thus, the tumor has many strategies to evade an immune response. It has been proposed that four different types of tumor microenvironment exist based on the presence or absence of tumor-infiltrating lymphocytes and programmed death-ligand 1 (PD-L1) expression. We review this stratification and the latest in a series of results that shed light on new approaches for rationally designing ideal combination cancer therapies based on tumor immunology.
在未来十年中，癌症免疫疗法可能会成为许多癌症的主要治疗支柱。在癌症中发现了众多免疫细胞类型以及针对癌症的免疫反应的许多组成部分。因此，肿瘤有多种逃避免疫反应的策略。基于肿瘤浸润淋巴细胞的存在与否以及程序性死亡配体1（PD-L1）的表达，有人提出存在四种不同类型的肿瘤微环境。我们回顾这种分层方法以及一系列最新研究结果，这些结果为基于肿瘤免疫学合理设计理想的联合癌症疗法的新方法提供了思路。
